mestinon 60 mg dragerad tablett
medartuum ab - pyridostigminbromid - dragerad tablett - 60 mg - pyridostigminbromid 60 mg aktiv substans; sackaros hjälpämne - pyridostigmin
oxycodone depot lannacher 10 mg depottablett
g.l. pharma gmbh - oxikodonhydroklorid - depottablett - 10 mg - sojalecitin hjälpämne; natriumlaurilsulfat hjälpämne; oxikodonhydroklorid 10 mg aktiv substans - oxikodon
oxycodone depot lannacher 20 mg depottablett
g.l. pharma gmbh - oxikodonhydroklorid - depottablett - 20 mg - sojalecitin hjälpämne; oxikodonhydroklorid 20 mg aktiv substans; natriumlaurilsulfat hjälpämne - oxikodon
oxycodone depot lannacher 40 mg depottablett
g.l. pharma gmbh - oxikodonhydroklorid - depottablett - 40 mg - oxikodonhydroklorid 40 mg aktiv substans; natriumlaurilsulfat hjälpämne; sojalecitin hjälpämne - oxikodon
oxycodone depot lannacher 5 mg depottablett
g.l. pharma gmbh - oxikodonhydroklorid - depottablett - 5 mg - natriumlaurilsulfat hjälpämne; sojalecitin hjälpämne; oxikodonhydroklorid 5 mg aktiv substans - oxikodon
oxycodone depot lannacher 80 mg depottablett
g.l. pharma gmbh - oxikodonhydroklorid - depottablett - 80 mg - sojalecitin hjälpämne; oxikodonhydroklorid 80 mg aktiv substans; natriumlaurilsulfat hjälpämne - oxikodon
venlafaxine bluefish 75 mg depotkapsel, hård
bluefish pharmaceuticals ab - venlafaxinhydroklorid - depotkapsel, hård - 75 mg - venlafaxinhydroklorid 84,9 mg aktiv substans; propylenglykol hjälpämne - venlafaxin
candur parvivo vet. injektionsvätska, suspension
intervet international b.v. - hundparvovirus, stam hp217, levande försvagat - injektionsvätska, suspension - hundparvovirus, stam hp217, levande försvagat 5,5 log10 tcid50 aktiv substans - hundparvovirus
lacosamide accord
accord healthcare s.l.u. - lakosamid - epilepsi - antiepileptika, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy• in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
lacosamide adroiq
extrovis eu ltd. - lakosamid - epilepsi - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.